Pyrazine Derivatives for BRG1/BRM Modulation in BAF Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with alterations in BRG1 and BRM proteins, which are components of the BAF complex, are inadequate.
Innovation Solution
Development of pyrazine derivatives that modulate the BAF complex by targeting BRG1 and BRM proteins, potentially in combination with other pharmaceutically active agents, to treat associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with BRG1 and BRM protein alterations, then existing therapeutic options are maintained, but treatment effectiveness is inadequate
Solution Approach 1:
The patent applies parameter changes by developing novel pyrazine derivative compounds with specific molecular structures (Formula I) that target BRG1 and BRM proteins. The chemical parameters of the compounds are optimized through varying substituents (R1, R2, X, L, B) to achieve effective modulation of BAF complex function, thereby improving treatment effectiveness for disorders associated with these protein alterations.
2Reliability
If pyrazine derivatives are developed to target BRG1 and BRM proteins, then treatment effectiveness is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into structured molecular components defined in Formula I. The pyrazine derivative is segmented into specific structural elements (ring system, substituents R1 and R2, linker L, degradation moiety B) with defined chemical properties, allowing systematic development and optimization while managing overall complexity.
Data Source
AI summary
The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.